Home
Product
Antibody
Biosimilar Antibodies
CD37 (ivicentamab Biosimilar) Recombinant Monoclonal Antibody

CD37 (ivicentamab Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA004928MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P11049

Target Names

CD37

Alternative Names

CD 37 antibody; CD37 antibody; CD37 antigen antibody; CD37 molecule antibody; CD37_HUMAN antibody; Cell differentiation antigen 37 antibody; GP52 40 antibody; Leukocyte antigen CD37 antibody; Leukocyte surface antigen CD37 antibody; MGC120234 antibody; Tetraspanin 26 antibody; Tetraspanin-26 antibody; Tetraspanin26 antibody; TSPAN 26 antibody; Tspan-26 antibody; TSPAN26 antibody

Species Reactivity

Human

Immunogen

Recombinant Human CD37 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

0.01M PBS，pH7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to ivicentamab, targeting CD37, a tetraspanin transmembrane glycoprotein predominantly expressed on B cells throughout their development and maturation. CD37 plays important roles in B cell signaling, immune regulation, and cellular organization through its association with other membrane proteins in tetraspanin-enriched microdomains. Aberrant CD37 expression is characteristic of various B cell malignancies, including chronic lymphocytic leukemia, non-Hodgkin lymphoma, and other B cell-derived cancers, making it an attractive therapeutic target for hematological disorders.

Ivicentamab represents a novel immunotherapeutic approach designed to selectively target CD37-positive malignant B cells. This biosimilar antibody provides researchers with a valuable tool for investigating CD37-mediated signaling pathways, exploring B cell biology, and studying mechanisms of action in B cell malignancy models. It supports preclinical research in oncology, immunology, and antibody-based therapeutic development, enabling detailed characterization of CD37 function and its role in disease pathogenesis.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Gene References into Functions

CD37 is a critical determinant of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone outcome in diffuse large B-cell lymphoma. PMID:27760757
Data indicate that cell differentiation antigen 37 (CD37) is well expressed and a potential drug target in acute myeloid leukemia (AML). PMID:25934707
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. PMID:24445867
Data indicate that enhanced antibody-dependent cell cytotoxicity (ADCC) is observed against chronic lymphocytic leukemia cells and is sustained at concentrations of SMIP-016(GV) as low at 5E(-6) microg/mL on cells expressing minimal CD37 antigen. PMID:23883821
Identify two tyrosine residues in tetraspanin CD37 directly mediating transduction of survival and apoptotic signals. PMID:22624718
In the absence of both CD37 and Tssc6, immune function is further altered when compared with CD37- or Tssc6-deficient transgenic mice, demonstrating a complementary role for these two molecules in cellular immunity. PMID:20709950
CD37 cross-linking on human T cells transduces signals that lead to complete inhibition of CD3-induced T cell proliferation. PMID:14978098
CD37 is important for dectin-1 stabilization in APC membranes and controls dectin-1-mediated IL-6 production. PMID:17182550
provide strong justification for CD37 as a therapeutic target and introduce small modular immunopharmaceuticals as a novel class of targeted therapies for B-cell malignancies PMID:17440052